Literature DB >> 15573922

RCAS1, a useful serum marker to predict the recurrence of cancer: two cases of cholangiocarcinoma and pancreatic cancer.

Munechika Enjoji1, Makoto Nakamuta, Koji Yamaguchi, Kazuhiro Kotoh, Shusuke Morizono, Eiichiro Arimura, Marie Fukushima, Masami Kuniyoshi, Manabu Nakashima, Masao Tanaka, Hajime Nawata.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15573922     DOI： 10.1023/b:ddas.0000043381.87424.c3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  12 in total

1.  Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.

Authors:  U Harmenberg; B Wahren; K L Wiechel
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

2.  Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1.

Authors:  M Nakashima; K Sonoda; T Watanabe
Journal:  Nat Med       Date:  1999-08       Impact factor: 53.440

3.  The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract.

Authors:  Munechika Enjoji; Manabu Nakashima; Hidehiro Nishi; Ilseung Choi; Hideki Oimomi; Rie Sugimoto; Kazuhiro Kotoh; Ken ichi Taguchi; Makoto Nakamuta; Hajime Nawata; Takeshi Watanabe
Journal:  J Hepatol       Date:  2002-06       Impact factor: 25.083

Review 4.  The clinical utility of the CA 19-9 tumor-associated antigen.

Authors:  W Steinberg
Journal:  Am J Gastroenterol       Date:  1990-04       Impact factor: 10.864

5.  Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias.

Authors:  K Sonoda; T Kaku; T Kamura; M Nakashima; T Watanabe; H Nakano
Journal:  Clin Cancer Res       Date:  1998-06       Impact factor: 12.531

6.  Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer.

Authors:  Tetsuro Akashi; Hideki Oimomi; Ken-ichi Nishiyama; Manabu Nakashima; Yoshiyuki Arita; Toshihiko Sumii; Toshinari Kimura; Tetsuhide Ito; Hajime Nawata; Takeshi Watanabe
Journal:  Pancreas       Date:  2003-01       Impact factor: 3.327

7.  Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases.

Authors:  M Enjoji; K Yamaguchi; M Nakamuta; M Nakashima; K Kotoh; M Tanaka; H Nawata; T Watanabe
Journal:  Dig Liver Dis       Date:  2004-09       Impact factor: 4.088

8.  Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.

Authors:  H Jalanko; P Kuusela; P Roberts; P Sipponen; C A Haglund; O Mäkelä
Journal:  J Clin Pathol       Date:  1984-02       Impact factor: 3.411

9.  CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.

Authors:  M Paganuzzi; M Onetto; P Marroni; D Barone; M Conio; H Aste; V Pugliese
Journal:  Cancer       Date:  1988-05-15       Impact factor: 6.860

10.  A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas.

Authors:  K Sonoda; M Nakashima; T Kaku; T Kamura; H Nakano; T Watanabe
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860
View more
  2 in total

1.  The role of RCAS1 as a biomarker in diagnosing CRC and monitoring tumor recurrence and metastasis.

Authors:  Su-xia Han; Jing Wang; Li-juan Wang; Gui-hua Jin; Xia Ying; Chen-chen He; Xi-jing Guo; Jian-ying Zhang; Ying Zhang; Qing Zhu
Journal:  Tumour Biol       Date:  2014-03-21

2.  Clinical significance of tumor-associated antigen RCAS1 expression in human pancreatic ductal adenocarcinoma.

Authors:  Constantinos Giaginis; Demetrios Davides; Apostolos Zarros; Olga Noussia; Adamantia Zizi-Serbetzoglou; Gregorios Kouraklis; Stamatios Theocharis
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.